The Aurora Kinase B pipeline drugs market research report outlays comprehensive information on the Aurora Kinase B targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Aurora Kinase B pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology which include the indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), and Gastric Cancer. It also reviews key players involved in Aurora Kinase B targeted therapeutics development with respective active and dormant or discontinued products.
The Aurora Kinase B pipeline targets constitutes close to 11 molecules. Out of which, approximately nine molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, IND/ CTA Filed, Preclinical, and Discovery stages are 1, 3, 1, 3, and 1 respectively. Similarly, the universities portfolio in Preclinical comprises 2 molecule.
Aurora Kinase B overview
Aurora B kinase is a protein that functions in the attachment of the mitotic spindle to the centromere. It is involved in the bipolar attachment of spindle microtubules to kinetochores and is a key regulator for the onset of cytokinesis during mitosis. It is required for central spindle assembly and cleavage furrow formation. It plays an important role in cytokinesis checkpoint. Phosphorylation of INCENP leads to increased AURKB activity. Other AURKB substrates involved in centromeric functions and mitosis are CENPA, DES/desmin, GPAF, KIF2C, NSUN2, RACGAP1, SEPT1, VIM/vimentin, GSG2/Haspin, and histone H3.
For a complete picture of Aurora Kinase B’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
